EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study

Yan Wu, Fang Fang, Wei Lai, Chengxin Li, Li Li, Quanzhong Liu, Jianyun Lu, Xiaowen Pang, Jiaming Sun, Xiaofeng Shi, Philippe Picaut, Inna Prygova und 2 weitere

Aesthetic Plastic Surgery · 2023-02 · 47 (1) · 351-364

DOI: 10.1007/s00266-022-03164-3 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Aesthetic Plastic Surgery, online erschienen am 19.12.2022. Verfasst von Yan Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Peking University First Hospital, No. 8 Xishiku Street, Xicheng, Beijing, 100034, China. 3437477565@qq.com. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Agents, Skin Aging. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ipsen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Various botulinumtoxinA formulations are approved for glabellar lines treatment worldwide, including abobotulinumtoxinA (Dysport ® ).

Objectives

Assess abobotulinumtoxinA superiority versus placebo and non-inferiority versus active comparator (onabotulinumtoxinA; Botox ® ), for the treatment of Chinese patients with moderate/severe glabellar lines.

Methods

Phase 3, randomized study (NCT02450526) comprising a double-blind (cycle 1) phase and an open-label (cycles 2−5) phase. Patients received abobotulinumtoxinA 50 units or matching placebo (5:1), active comparator (onabotulinumtoxinA 20 units) or matching placebo (5:1). In cycles 2–5, eligible patients were retreated with abobotulinumtoxinA only. Responders had glabellar lines of none/mild severity. Primary endpoint: responder rates at cycle 1, day 29 at maximum frown with abobotulinumtoxinA versus placebo (for superiority; by investigator’s live assessment [ILA] and subject’s self-assessment [SSA]), and versus active comparator (for non-inferiority; by ILA). Treatment-emergent adverse events were recorded.

Results

Overall, 520 patients were randomized. Superiority and non-inferiority, respectively, were demonstrated for abobotulinumtoxinA versus placebo (ILA, SSA; both p < 0.0001) and abobotulinumtoxinA versus active comparator. AbobotulinumtoxinA efficacy was maintained over open-label cycles; median time to onset of efficacy was 2.0 days. After 6 months, 17% of patients treated with abobotulinumtoxinA remained responders. AbobotulinumtoxinA was well-tolerated. Safety results were in line with the known profile of abobotulinumtoxinA; adverse events rate decreased with repeated treatment.

Conclusions

After a single injection, abobotulinumtoxinA demonstrated superiority versus placebo and non-inferiority versus onabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines in Chinese patients. Multiple injections of abobotulinumtoxinA demonstrated efficacy and safety in the treatment of glabellar lines in Chinese patients. Level of Evidence I This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ANeuromuscular AgentsSkin AgingHumansDouble-Blind MethodEast Asian PeopleForeheadTreatment Outcome

Substanzen

abobotulinumtoxinABotulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Peking University First Hospital, No. 8 Xishiku Street, Xicheng, Beijing, 100034, China. 3437477565@qq.com.
  • Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, China.
  • Department of Dermatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • General Hospital of People's Liberation Army (301 Hospital), Beijing, China.
  • West China Hospital, Sichuan University, Chengdu, China.
  • Tianjin Medical University General Hospital, Tianjin, China.

Förderung

  • Ipsen

Zitieren

APA

Wu, Y., Fang, F., Lai, W., Li, C., Li, L., Liu, Q., Lu, J., Pang, X., Sun, J., Shi, X., Picaut, P., Prygova, I., Andriopoulos, B., & Sun, Q. (2023). Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study. Aesthetic Plastic Surgery, 47(1), 351-364. https://doi.org/10.1007/s00266-022-03164-3

Vancouver

Wu Y, Fang F, Lai W, Li C, Li L, Liu Q, et al. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study. Aesthetic Plastic Surgery. 2023;47(1):351-364. doi:10.1007/s00266-022-03164-3

BibTeX
@article{Wu2023,
  author = {Wu, Yan and Fang, Fang and Lai, Wei and Li, Chengxin and Li, Li and Liu, Quanzhong and Lu, Jianyun and Pang, Xiaowen and Sun, Jiaming and Shi, Xiaofeng and Picaut, Philippe and Prygova, Inna and Andriopoulos, Bill and Sun, Qiuning},
  title = {Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study},
  journal = {Aesthetic Plastic Surgery},
  year = {2023},
  volume = {47},
  number = {1},
  pages = {351--364},
  doi = {10.1007/s00266-022-03164-3}
}
Kostenlos starten →